Literature DB >> 30038036

Ebola Immunity: Gaining a Winning Position in Lightning Chess.

Aurélie Ploquin1, Yan Zhou1, Nancy J Sullivan2.   

Abstract

Zaire ebolavirus (EBOV), one of five species in the genus Ebolavirus, is the causative agent of the hemorrhagic fever disease epidemic that claimed more than 11,000 lives from 2014 to 2016 in West Africa. The combination of EBOV's ability to disseminate broadly and rapidly within the host and its high pathogenicity pose unique challenges to the human immune system postinfection. Potential transmission from apparently healthy EBOV survivors reported in the recent epidemic raises questions about EBOV persistence and immune surveillance mechanisms. Clinical, virological, and immunological data collected since the West Africa epidemic have greatly enhanced our knowledge of host-virus interactions. However, critical knowledge gaps remain in our understanding of what is necessary for an effective host immune response for protection against, or for clearance of, EBOV infection. This review provides an overview of immune responses against EBOV and discusses those associated with the success or failure to control EBOV infection.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30038036     DOI: 10.4049/jimmunol.1700827

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

Review 1.  Genomics and High-Consequence Infectious Diseases: A Scoping Review of Emerging Science and Potential Ethical Issues.

Authors:  Angie M Boyce; Brian T Garibaldi
Journal:  Health Secur       Date:  2019-02-06

2.  A modular framework for multiscale, multicellular, spatiotemporal modeling of acute primary viral infection and immune response in epithelial tissues and its application to drug therapy timing and effectiveness.

Authors:  T J Sego; Josua O Aponte-Serrano; Juliano Ferrari Gianlupi; Samuel R Heaps; Kira Breithaupt; Lutz Brusch; Jessica Crawshaw; James M Osborne; Ellen M Quardokus; Richard K Plemper; James A Glazier
Journal:  PLoS Comput Biol       Date:  2020-12-21       Impact factor: 4.475

3.  Added Value of an Anti-Ebola Serology for the Management of Clinically Suspected Ebola Virus Disease Patients Discharged as Negative in an Epidemic Context.

Authors:  Antoine Nkuba-Ndaye; Daniel Mukadi-Bamuleka; Junior Bulabula-Penge; Guillaume Thaurignac; François Edidi-Atani; Fabrice Mambu-Mbika; Bernice Danga-Yema; Meris Matondo-Kuamfumu; Eddy Kinganda-Lusamaki; Nella Bisento; Raphaël Lumembe-Numbi; Gabriel Kabamba-Lungenyi; Divine Kitsa-Mutsumbirwa; Nelson Kambale-Sivihwa; François Boillot; Eric Delaporte; Placide Mbala-Kingebeni; Ahidjo Ayouba; Martine Peeters; Steve Ahuka-Mundeke
Journal:  J Infect Dis       Date:  2022-08-24       Impact factor: 7.759

4.  Ebola virus glycoprotein stimulates IL-18-dependent natural killer cell responses.

Authors:  Helen R Wagstaffe; Elizabeth A Clutterbuck; Viki Bockstal; Jeroen N Stoop; Kerstin Luhn; Macaya Douoguih; Georgi Shukarev; Matthew D Snape; Andrew J Pollard; Eleanor M Riley; Martin R Goodier
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

5.  Designs and Characterization of Subunit Ebola GP Vaccine Candidates: Implications for Immunogenicity.

Authors:  Valentina Agnolon; Divor Kiseljak; Maria J Wurm; Florian M Wurm; Charlotte Foissard; Fabrice Gallais; Sarah Wehrle; César Muñoz-Fontela; Laurent Bellanger; Bruno Emanuel Correia; Giampietro Corradin; François Spertini
Journal:  Front Immunol       Date:  2020-11-04       Impact factor: 7.561

6.  PET imaging of TSPO expression in immune cells can assess organ-level pathophysiology in high-consequence viral infections.

Authors:  Swati Shah; Sanhita Sinharay; Reema Patel; Jeffrey Solomon; Ji Hyun Lee; William Schreiber-Stainthorp; Falguni Basuli; Xiang Zhang; Katie R Hagen; Rebecca Reeder; Paul Wakim; Louis M Huzella; Dragan Maric; Reed F Johnson; Dima A Hammoud
Journal:  Proc Natl Acad Sci U S A       Date:  2022-04-06       Impact factor: 12.779

Review 7.  Nanotechnology-Based siRNA Delivery Systems to Overcome Tumor Immune Evasion in Cancer Immunotherapy.

Authors:  Kaili Deng; Dongxue Yang; Yuping Zhou
Journal:  Pharmaceutics       Date:  2022-06-25       Impact factor: 6.525

8.  Ebola virus protein VP40 stimulates IL-12- and IL-18-dependent activation of human natural killer cells.

Authors:  Hung Le; Paul Spearman; Stephen N Waggoner; Karnail Singh
Journal:  JCI Insight       Date:  2022-08-22

Review 9.  Ebola virus disease.

Authors:  Shevin T Jacob; Ian Crozier; William A Fischer; Angela Hewlett; Colleen S Kraft; Marc-Antoine de La Vega; Moses J Soka; Victoria Wahl; Anthony Griffiths; Laura Bollinger; Jens H Kuhn
Journal:  Nat Rev Dis Primers       Date:  2020-02-20       Impact factor: 52.329

10.  Natural history of disease in cynomolgus monkeys exposed to Ebola virus Kikwit strain demonstrates the reliability of this non-human primate model for Ebola virus disease.

Authors:  Nancy A Niemuth; Dawn Fallacara; Cheryl A Triplett; Sanjay M Tamrakar; Alisha Rajbhandari; Clint Florence; Lucy Ward; Anthony Griffiths; Ricardo Carrion; Yenny Goez-Gazi; Kendra J Alfson; Hilary M Staples; Trevor Brasel; Jason E Comer; Shane Massey; Jeanon Smith; Andrew Kocsis; Jake Lowry; Sara C Johnston; Aysegul Nalca; Arthur J Goff; Amy C Shurtleff; Margaret L Pitt; John Trefry; Michael P Fay
Journal:  PLoS One       Date:  2021-07-02       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.